P7C3-A20-DataSheet-生命科学试剂-MedChemExpress

Hotline:400-820-3792Inhibitors•ScreeningLibraries•Proteinswww.MedChemEP7C3-A20Cat.No.:HY-15978CASNo.:1235481-90-9分⼦式:C₂₂H₁₉Br₂FN₂O分⼦量:506.21作⽤靶点:Others作⽤通路:Others储存⽅式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性数据体外实验DMSO:≥100mg/mL(197.55mM)*"≥"meanssoluble,butsaturationunknown.MassSolvent1mg5mg10mgConcentration制备储备液1mM1.9755mL9.8773mL19.7546mL5mM0.3951mL1.9755mL3.9509mL10mM0.1975mL0.9877mL1.9755mL请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。储备液的保存⽅式和期限：-80°C,6months;-20°C,1month。-80°C储存时，请在6个⽉内使⽤，-20°C储存时，请在1个⽉内使⽤。体内实验请根据您的实验动物和给药⽅式选择适当的溶解⽅案。以下溶解⽅案都请先按照InVitro⽅式配制澄的储备液，再依次添加助溶剂：(为保证实验结果的可靠性，澄的储备液可以根据储存条件，适当保存；体内实验的⼯作液，建议您现⽤现配，当天使⽤；以下溶剂前显⽰的百分⽐指该溶剂在您配制终溶液中的体积占⽐；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的⽅式助溶)1.请依序添加每种溶剂：10%DMSO>>40%PEG300>>5%Tween-80>>45%saline1/3MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemESolubility:≥3.85mg/mL(7.61mM);Clearsolution2.请依序添加每种溶剂：10%DMSO>>90%cornoilSolubility:≥2.5mg/mL(4.94mM);ClearsolutionBIOLOGICALACTIVITY⽣物活性P7C3-A20⼀种具有有效的促神经原性和神经保护活性的P7C3衍⽣物。P7C3-A20具有抗抑郁作⽤，可以穿越⾎脑屏障，并可⽤于脑损伤的研究。体外研究P7C3-A20(10-100μM;8hours;PC12cells)treatmentalleviatesoxygen-glucosedeprivation(OGD)-inducedcytotoxicityinPC12cells[1].P7C3-A20(40-100μM;8hours;PC12cells)treatmentalleviatesOGD-inducedapoptosisinPC12cells[1].CellViabilityAssay[1]CellLine:PC12cellsConcentration:10ꢀμM,20μM,40ꢀμM,60μM,80ꢀμM,100μMIncubationTime:8hoursResult:Alleviatedoxygen-glucosedeprivation(OGD)-inducedcytotoxicityinPC12cells.ApoptosisAnalysis[1]CellLine:PC12cellsConcentration:40ꢀμM,60μM,80ꢀμM,100μMIncubationTime:8hoursResult:Alleviatedoxygen-glucosedeprivation(OGD)-inducedapoptosisinPC12cells.体内研究P7C3-A20(5-10ꢀmg/kg;intraperitonealinjection;daily;for7days;Sprague-Dawleyrats)treatmentreducesinfarctvolume;reversescelllossinthecortexandhippocampusandimprovesmotorfunctionwithoutcausingneurotoxicityinHImodelrats.P7C3-A20preventsHI-inducedneuronalinjuryviaactivationofthePI3K/AKT/GSK3βsignalingpathway[1].AnimalModel:Sprague-Dawleyrats(200-250g)inducedhypoxic-ischemic(HI)injury[1]Dosage:5ꢀmg/kg,10ꢀmg/kgAdministration:Intraperitonealinjection;daily;for7daysResult:Reducedinfarctvolume;reversedcelllossinthecortexandhippocampusandimprovedmotorfunctionwithoutcausingneurotoxicity.2/3MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemE户使⽤本产品发表的科研⽂献•CircRes.2021May28;128(11):1629-1641.•Neuroscience.2020Aug10;441:197-208.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].BlayaMOetal.Neuroprotectiveefficacyofaproneurogeniccompoundaftertraumaticbraininjury.JNeurotrauma.2014Mar1;31(5):476-86.[2].WalkerAKetal.TheP7C3classofneuroprotectivecompoundsexertsantidepressantefficacyinmicebyincreasinghippocampalneurogenesis.MolPsychiatry.2015Apr;20(4):500-8.[3].JunjieBai,etal.TheSmallMoleculeP7C3-A20ExertsNeuroprotectiveEffectsinaHypoxic-IschemicEncephalopathyModelviaActivationofPI3K/AKT/GSK3βSignaling.Neuroscience.2020Jun3;S0306-4522(20)30353-5.McePdfHeightCaution:Producthasnotbeenfully